Seer CFO departure signals routine leadership change at proteomics firm

David Horn exits Seer after six years as CFO, replaced internally by VP of Financial Planning Charles Endweiss from October.

By Disrupts Editorial Team Sun, 4 October 2026 AI level 2 of 5

AI level 2 of 5: drafted by our AI editorial assistant from the company's announcement; fact-checked, edited and signed off by Mark Walker, Editorial Director. What the levels mean

A complex, shiny metallic laboratory machine with numerous components, tubes, vials, and a control panel stands in a brightly lit, modern laboratory featuring large windows and white lab tables.

Seer, Inc. (Nasdaq: SEER), the Redwood City proteomics company behind the Proteograph Product Suite, has announced that David Horn, its President, Chief Financial Officer and Treasurer, will leave the business on 1 October 2026 to join a private company. Charles Endweiss, currently Vice President of Financial Planning and Analysis, will step into the principal financial officer role on the same date.

The transition is an internal promotion rather than an external hire, with Endweiss having served Seer's finance function since January 2021. Prior to joining Seer, he held a business operations role at Carbon, the digital 3D-printing and manufacturing platform, and earlier held accounting and finance positions across several technology companies.

A quiet handover at a listed deep-tech firm

Horn's departure follows more than six years at Seer, a period that included the company's Nasdaq listing and its efforts to commercialise nanoparticle-enabled proteomics technology. CEO Omid Farokhzad described Horn as having guided the company through "a pivotal period," though no financial metrics, strategic milestones, or forward programme detail accompanied the announcement.

The release is notably sparse on operational substance. There are no revenue figures, no update on the commercialisation trajectory of the Proteograph suite, and no commentary on pipeline or capital position. Seer's products carry a research-use-only designation and are not approved for diagnostic procedures, meaning the company remains in a pre-revenue or early-revenue phase typical of deep-science instrumentation businesses.

Limited cross-sector read-across

For Disrupts readers tracking the broader proteomics-meets-AI-infrastructure theme, Seer is a company worth watching contextually: unbiased, large-scale proteomic data sets are increasingly cited as a missing upstream input for multimodal biological foundation models. However, this announcement contributes nothing to that narrative. It is a personnel transition with standard boilerplate forward-looking-statement caveats, no capital allocation signal, and no indication of strategic direction change.

The internal succession pattern (a long-tenured FP&A lead stepping up rather than an external CFO being recruited) could suggest the board is in a consolidation rather than expansion mode, but that reading is speculative given the absence of supporting data in the release.